Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation

Alberto Antonicelli, Stefano Cafarotti, Alice Indini, Alessio Galli, Andrea Russo, Alfredo Cesario, Filippo Maria Lococo, Patrizia Russo, Alberto Franco Mainini, Luca Giuseppe Bonifati, Mario Nosotti, Luigi Santambrogio, Stefano Margaritora, Pierluigi Maria Granone, André Emanuel Dutly

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs). This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient- tailored therapy could be closer than commonly expected.

Original languageEnglish
Pages (from-to)320-330
Number of pages11
JournalInternational Journal of Medical Sciences
Volume10
Issue number3
DOIs
Publication statusPublished - Feb 11 2013

Fingerprint

Mutation
Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Oncogenes
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Squamous Cell Carcinoma
Adenocarcinoma
Pharmacology
Survival

Keywords

  • Advanced
  • EGFR targeted therapy
  • Mutation
  • NSCLC
  • Resistance
  • TKIs

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egfr-targeted therapy for non-small cell lun cancer : Focus on EGFR oncogenic mutation. / Antonicelli, Alberto; Cafarotti, Stefano; Indini, Alice; Galli, Alessio; Russo, Andrea; Cesario, Alfredo; Lococo, Filippo Maria; Russo, Patrizia; Mainini, Alberto Franco; Bonifati, Luca Giuseppe; Nosotti, Mario; Santambrogio, Luigi; Margaritora, Stefano; Granone, Pierluigi Maria; Dutly, André Emanuel.

In: International Journal of Medical Sciences, Vol. 10, No. 3, 11.02.2013, p. 320-330.

Research output: Contribution to journalArticle

Antonicelli, A, Cafarotti, S, Indini, A, Galli, A, Russo, A, Cesario, A, Lococo, FM, Russo, P, Mainini, AF, Bonifati, LG, Nosotti, M, Santambrogio, L, Margaritora, S, Granone, PM & Dutly, AE 2013, 'Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation', International Journal of Medical Sciences, vol. 10, no. 3, pp. 320-330. https://doi.org/10.7150/ijms.4609
Antonicelli, Alberto ; Cafarotti, Stefano ; Indini, Alice ; Galli, Alessio ; Russo, Andrea ; Cesario, Alfredo ; Lococo, Filippo Maria ; Russo, Patrizia ; Mainini, Alberto Franco ; Bonifati, Luca Giuseppe ; Nosotti, Mario ; Santambrogio, Luigi ; Margaritora, Stefano ; Granone, Pierluigi Maria ; Dutly, André Emanuel. / Egfr-targeted therapy for non-small cell lun cancer : Focus on EGFR oncogenic mutation. In: International Journal of Medical Sciences. 2013 ; Vol. 10, No. 3. pp. 320-330.
@article{afa77e539594405db2125acb327209bb,
title = "Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation",
abstract = "The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs). This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient- tailored therapy could be closer than commonly expected.",
keywords = "Advanced, EGFR targeted therapy, Mutation, NSCLC, Resistance, TKIs",
author = "Alberto Antonicelli and Stefano Cafarotti and Alice Indini and Alessio Galli and Andrea Russo and Alfredo Cesario and Lococo, {Filippo Maria} and Patrizia Russo and Mainini, {Alberto Franco} and Bonifati, {Luca Giuseppe} and Mario Nosotti and Luigi Santambrogio and Stefano Margaritora and Granone, {Pierluigi Maria} and Dutly, {Andr{\'e} Emanuel}",
year = "2013",
month = "2",
day = "11",
doi = "10.7150/ijms.4609",
language = "English",
volume = "10",
pages = "320--330",
journal = "International Journal of Medical Sciences",
issn = "1449-1907",
publisher = "Ivyspring International Publisher",
number = "3",

}

TY - JOUR

T1 - Egfr-targeted therapy for non-small cell lun cancer

T2 - Focus on EGFR oncogenic mutation

AU - Antonicelli, Alberto

AU - Cafarotti, Stefano

AU - Indini, Alice

AU - Galli, Alessio

AU - Russo, Andrea

AU - Cesario, Alfredo

AU - Lococo, Filippo Maria

AU - Russo, Patrizia

AU - Mainini, Alberto Franco

AU - Bonifati, Luca Giuseppe

AU - Nosotti, Mario

AU - Santambrogio, Luigi

AU - Margaritora, Stefano

AU - Granone, Pierluigi Maria

AU - Dutly, André Emanuel

PY - 2013/2/11

Y1 - 2013/2/11

N2 - The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs). This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient- tailored therapy could be closer than commonly expected.

AB - The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs). This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient- tailored therapy could be closer than commonly expected.

KW - Advanced

KW - EGFR targeted therapy

KW - Mutation

KW - NSCLC

KW - Resistance

KW - TKIs

UR - http://www.scopus.com/inward/record.url?scp=84873725755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873725755&partnerID=8YFLogxK

U2 - 10.7150/ijms.4609

DO - 10.7150/ijms.4609

M3 - Article

C2 - 23423768

AN - SCOPUS:84873725755

VL - 10

SP - 320

EP - 330

JO - International Journal of Medical Sciences

JF - International Journal of Medical Sciences

SN - 1449-1907

IS - 3

ER -